Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial

Clin Infect Dis. 2021 Aug 16;73(4):e1008-e1010. doi: 10.1093/cid/ciab086.

Abstract

Following evidence of HIV RNA re-suppression on DTG-based regimens, we assess the re-suppressive capacity of ADVANCE participants on TAF/FTC+DTG, TDF/FTC+DTG, and TDF/FTC/EFV. Viraemic participants were able to re-suppress within 3 follow-up visits of protocol-defined virological failure (PDVF) in 77/121 (64%), 85/126 (67%), and 44/138 (32%) cases respectively (DTG regimens vs. TDF/FTC/EFV; P < 0.001).

Keywords: HIV; adherence; antiretrovirals; dolutegravir; resuppression.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • HIV / genetics
  • HIV Infections* / drug therapy
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Oxazines
  • Piperazines
  • Pyridones
  • RNA / therapeutic use

Substances

  • Anti-HIV Agents
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • RNA
  • dolutegravir